Related Experiment Videos
Molecular therapeutic target for type-2 diabetes
1Gordon Life Science Institute, San Diego, CA 92130, USA. kchou@san.rr.com
Journal of Proteome Research
|December 15, 2004
Summary
Increased glucose metabolism via glutamine:fructose-6-phosphate amidotransferase (GFAT) contributes to type-2 diabetes. Targeting GFAT and its UDP-GlcNAc interaction offers a novel therapeutic strategy for diabetes treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Increased glucose flux, catalyzed by glutamine:fructose-6-phosphate amidotransferase (GFAT), is linked to insulin resistance in type-2 diabetes.
- Uridine-5'-diphosphate-N-acetylglucosamine (UDP-GlcNAc) acts as an energy sensor within this pathway.
Purpose of the Study:
- To investigate GFAT and its interaction with UDP-GlcNAc as a potential therapeutic target for type-2 diabetes.
- To facilitate structure-based drug design by elucidating the three-dimensional structures of human GFAT1.
Main Methods:
- Development of three-dimensional structures for human GFAT1 monomer and dimer.
- Molecular docking of UDP-GlcNAc to the GFAT1 dimer interface.
Main Results:
- UDP-GlcNAc binds to the dimer interface of human GFAT1 via 12 hydrogen bonds.
- A specific binding pocket for UDP-GlcNAc on the human GFAT1 dimer was defined.
Conclusions:
- The structural insights into GFAT1-UDP-GlcNAc interaction provide a foundation for developing novel therapeutic strategies.
- Targeting GFAT offers a promising avenue for the treatment of type-2 diabetes.